Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct. 1, 2014 Dec. 31, 2015 No Longer Used
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan. 1, 2016 In Use
J9310 Rituximab Rituxan 100 mg Immunotherapy Monoclonal Antibody CD20 No 1997 Jan. 1, 1999 In Use
C9455 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 July 1, 2015 Dec. 31, 2015 No Longer Used
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan. 1, 2016 In Use
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct. 1, 2010 June 30, 2011 No Longer Used
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 July 1, 2011 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan. 1, 2017 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 April 1, 2016 In Use
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
A9534 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic per MC Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 July 1, 2003 In Use
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan. 1, 2006 In Use
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan. 1, 2000 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan. 1, 2003 In Use
J8499 Immunotherapy - non specific Prescription drug, oral, non chemotherapeutic, nos NA Immunotherapy Yes Jan. 1, 1995 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan. 1, 2002 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No April 1, 2002 In Use
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
J0128 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
S0165 Abarelix Plenaxis 100 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use

Found 716 results in 4 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.